Hypoglycemia Screener and Glucagon Gap-Closer for Diabetes Clinics
A clinic tool that tracks low-blood-sugar episodes to identify patients who need rescue kits.
A clinic add-on that asks a few standardized questions about low-blood-sugar episodes at every diabetes visit, grades them by ADA severity levels in a registry, and automatically flags patients who need a glucagon rescue kit or a medication change.
Concept
A clinic workflow module that puts the ADA's hypoglycemia assessment into structured form at every diabetes encounter. The patient answers a short standardized question set (waiting room, portal, or rooming), and the tool grades each reported low-glucose event by the ADA's severity levels, screens for hypoglycemia unawareness, and writes discrete data to a practice-wide hypoglycemia registry. From the registry it auto-produces two actionable worklists:
- Glucagon gap list — patients with severe or recurrent events (or unawareness) who have no active glucagon prescription, routed to the prescriber for one-click rescue-kit ordering.
- Regimen review list — patients whose events trace to hypoglycemia-prone regimens, routed for de-intensification per the pharmacologic standards [1].
Where CGM data exist, meter-flagged lows flow into the same registry [3], so the practice sees one hypoglycemia picture regardless of monitoring modality.
Why now
The 2026 Standards [0] give hypoglycemia a dedicated place in the glycemic-goals chapter — its classification, its assessment at encounters, and its rescue treatment — establishing it as the explicit limiting factor in reaching glycemic targets. In routine care, hypoglycemia lives in free-text notes, so practices cannot quantify their burden, cannot find the patients who most need a glucagon kit, and cannot report hypoglycemia as a quality measure even though the Standards are explicitly designed to support quality-of-care evaluation [0]. CGM catches lows for the monitored minority [3], but structured visit-based capture is the only channel that reaches everyone — and the annual revision cycle [0] keeps the grading and management logic current.
Written by GLM · 11 Oct 2026
AI assessment
A highly practical, low-risk clinical workflow tool that converts ADA guidelines into a structured safety net for hypoglycemia management.
- Evidence strength 5/5
- The idea directly implements the 2026 ADA Standards of Care, which explicitly define the classification and assessment of hypoglycemia as a quality-of-care metric.
- Market pull 4/5
- Large health systems and endocrinology clinics have a strong incentive to reduce hypoglycemia-related ER visits and improve adherence to safety standards.
- Novelty & moat 3/5
- While it shares the 'case-finder' logic of existing catalog ideas, it targets a distinct clinical gap (rescue kit gaps and regimen de-intensification) rather than just device eligibility.
- Feasibility 5/5
- The tool relies on simple structured questionnaires and basic logic gates, making it an easy build as an EHR plugin or standalone module.
- Wedge clarity 5/5
- The 'Glucagon gap list' is a sharp, high-value entry point that provides immediate, tangible safety improvements for the clinic.
- Simplicity / focus 5/5
- The product is focused on a single clinical problem—hypoglycemia screening—without sprawling into an unrelated platform.
Scored by Gemma 4 · 11 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
Diabetes care and education specialists are the workforce expected to assess hypoglycemia at every encounter; a structured screener standardizes their visits and gives them outcome data they currently lack.
- Joslin Diabetes Centerorganization
Runs specialized hypoglycemia care and education programs; a practice-wide registry surfaces their highest-risk patients and documents hypoglycemia burden for referral and research.
- Eli Lilly and Companycompany
Maker of Baqsimi nasal glucagon; a tool that systematically identifies severe-hypoglycemia patients lacking a rescue prescription grows appropriate glucagon prescribing where it is most needed.
- Optum (UnitedHealth Group)company
Severe hypoglycemia drives avoidable emergency-room use among insured members with diabetes; the registry gives its case-management teams a ranked worklist of members to intervene on.
Research it builds on
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026Mandeep Singh Bajaj, Rozalina Grubina McCoy, Kirthikaa Balapattabi et al. · 2025 · 191 citationsAll ideas from this paper →
- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026Mandeep Singh Bajaj, Rozalina Grubina McCoy, Kirthikaa Balapattabi et al. · 2025 · 136 citationsAll ideas from this paper →
- 7. Diabetes Technology: Standards of Care in Diabetes—2026Mandeep Singh Bajaj, Rozalina Grubina McCoy, Kirthikaa Balapattabi et al. · 2025 · 136 citationsAll ideas from this paper →